{"transactions":[{"id":716387,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:10:32.000Z","date":"2026-06-30","kind":"other","planned":false,"acquired":true,"shares":132,"price":160.7095,"value":21213.654,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":199513,"source":{"system":"sec-edgar","filing":"0002001011-26-000106","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000106/edgardoc.xml","form_type":"4"}},{"id":737534,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T21:25:26.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":503,"price":28.7261,"value":14449.2283,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $28.72 to $28.94. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":75834,"source":{"system":"sec-edgar","filing":"0001919246-26-000088","document":"wk-form4_1781558723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000191924626000088/wk-form4_1781558723.xml","form_type":"4"}},{"id":737533,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T21:25:26.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":35445,"price":27.8046,"value":985534.047,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $27.63 to $28.49. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":75331,"source":{"system":"sec-edgar","filing":"0001919246-26-000088","document":"wk-form4_1781558723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000191924626000088/wk-form4_1781558723.xml","form_type":"4"}},{"id":739338,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:05:43.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":3000,"derivative":{"exercise_price":102.19,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-073426","document":"tm2617372-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000110465926073426/tm2617372-2_4seq1.xml","form_type":"4"}},{"id":822610,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:20.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":39886,"source":{"system":"sec-edgar","filing":"0001919246-26-000046","document":"wk-form4a_1775079918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000191924626000046/wk-form4a_1775079918.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822609,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:20.000Z","date":"2024-11-13","kind":"grant","planned":false,"acquired":true,"shares":4961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":20778,"source":{"system":"sec-edgar","filing":"0001919246-26-000046","document":"wk-form4a_1775079918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000191924626000046/wk-form4a_1775079918.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822608,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:20.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":12900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":15817,"source":{"system":"sec-edgar","filing":"0001919246-26-000046","document":"wk-form4a_1775079918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000191924626000046/wk-form4a_1775079918.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":826817,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-28T00:33:21.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":50058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter."}],"balance_after":50058,"derivative":{"exercise_price":202.55,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":50058},"source":{"system":"sec-edgar","filing":"0002001011-26-000033","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000033/primary_doc.xml","form_type":"4"}},{"id":826816,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-28T00:33:21.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":10495,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2027; February 15, 2028; and February 15, 2029, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Pursuant to an election under the Issuer's Nonqualified Deferred Compensation Plan, delivery of shares otherwise issuable upon each vesting date will be deferred."}],"balance_after":199381,"source":{"system":"sec-edgar","filing":"0002001011-26-000033","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000033/primary_doc.xml","form_type":"4"}},{"id":898616,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:21:54.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":2805,"price":183.83,"value":515643.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":188886,"source":{"system":"sec-edgar","filing":"0002001011-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000011/edgardoc.xml","form_type":"4"}},{"id":898615,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:21:54.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":4255,"price":183.83,"value":782196.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":191691,"source":{"system":"sec-edgar","filing":"0002001011-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000011/edgardoc.xml","form_type":"4"}},{"id":898614,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:21:54.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":2039,"price":183.83,"value":374829.37,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":195946,"source":{"system":"sec-edgar","filing":"0002001011-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000011/edgardoc.xml","form_type":"4"}},{"id":898613,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:21:54.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":15600,"price":183.83,"value":2867748.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs."}],"balance_after":197985,"source":{"system":"sec-edgar","filing":"0002001011-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000011/edgardoc.xml","form_type":"4"}},{"id":898612,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:21:54.000Z","date":"2026-02-14","kind":"grant","planned":false,"acquired":true,"shares":39644,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon the vesting and certification of performance stock units (\"PSUs\")."}],"balance_after":213585,"source":{"system":"sec-edgar","filing":"0002001011-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000011/edgardoc.xml","form_type":"4"}},{"id":898611,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:21:54.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":8178,"price":183.83,"value":1503361.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs."}],"balance_after":173941,"source":{"system":"sec-edgar","filing":"0002001011-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000011/edgardoc.xml","form_type":"4"}},{"id":898610,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:21:54.000Z","date":"2026-02-14","kind":"grant","planned":false,"acquired":true,"shares":20782,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon the vesting and certification of performance stock units (\"PSUs\")."}],"balance_after":182119,"source":{"system":"sec-edgar","filing":"0002001011-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000011/edgardoc.xml","form_type":"4"}},{"id":978264,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-09T00:37:58.000Z","date":"2025-12-04","kind":"gift","planned":false,"acquired":false,"shares":130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a bona fide gift of shares to a charitable entity."}],"balance_after":161337,"source":{"system":"sec-edgar","filing":"0002001011-25-000121","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000121/edgardoc.xml","form_type":"4"}},{"id":1091164,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-07-08T01:43:40.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":58230,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."}],"balance_after":58230,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":58230},"source":{"system":"sec-edgar","filing":"0001753926-25-001105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392625001105/ownership.xml","form_type":"4"}},{"id":1091163,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-07-08T01:43:40.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":36969,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":19108},"source":{"system":"sec-edgar","filing":"0001753926-25-001105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392625001105/ownership.xml","form_type":"4"}},{"id":1091915,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:02:33.000Z","date":"2025-07-01","kind":"other","planned":false,"acquired":true,"shares":31278.681,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"shares","element":"transactionShares","label":"F4","text":"Received in exchange for shares of LNHC, Inc. (\"LNHC\") common stock in connection with the merger of CHRO Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of the Issuer, with and into LNHC, a wholly-owned subsidiary of Ligand, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for shares of LNHC, Inc. (\"LNHC\") common stock in connection with the merger of CHRO Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of the Issuer, with and into LNHC, a wholly-owned subsidiary of Ligand, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. (\"Ligand\"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":3127868,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":3127868},"source":{"system":"sec-edgar","filing":"0001753926-25-001075","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392625001075/ownership.xml","form_type":"4"}},{"id":1091914,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:02:33.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. (\"Ligand\"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":3000,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001753926-25-001075","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392625001075/ownership.xml","form_type":"4"}},{"id":1091913,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-04T01:02:33.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":true,"shares":1500000,"price":10,"value":15000000.0,"ownership":{"direct":false,"nature":"By Ligand Pharmaceuticals Incorporated"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. (\"Ligand\"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":1500000,"source":{"system":"sec-edgar","filing":"0001753926-25-001075","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392625001075/ownership.xml","form_type":"4"}},{"id":1096619,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-02T23:31:45.000Z","date":"2025-06-30","kind":"other","planned":false,"acquired":true,"shares":233,"price":91.0775,"value":21221.0575,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":161467,"source":{"system":"sec-edgar","filing":"0002001011-25-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000050/edgardoc.xml","form_type":"4"}},{"id":1114679,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-11T23:59:24.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":12350,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12350,"derivative":{"exercise_price":26.23,"exercise_date":"2026-06-10","expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":12350},"source":{"system":"sec-edgar","filing":"0001583648-25-000038","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000158364825000038/edgardoc.xml","form_type":"4"}},{"id":1151511,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-14T00:05:16.000Z","date":"2025-05-09","kind":"purchase","planned":false,"acquired":true,"shares":5523,"price":105.6725,"value":583629.2175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $105.1300 to $106.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":161234,"source":{"system":"sec-edgar","filing":"0002001011-25-000029","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000029/edgardoc.xml","form_type":"4"}},{"id":1151510,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-14T00:05:16.000Z","date":"2025-05-09","kind":"purchase","planned":false,"acquired":true,"shares":2307,"price":104.5295,"value":241149.5565,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $104.1300 to $105.1000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":155711,"source":{"system":"sec-edgar","filing":"0002001011-25-000029","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000029/edgardoc.xml","form_type":"4"}},{"id":1151509,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-14T00:05:16.000Z","date":"2025-05-09","kind":"purchase","planned":false,"acquired":true,"shares":1680,"price":104.57,"value":175677.6,"ownership":{"direct":true},"balance_after":153404,"source":{"system":"sec-edgar","filing":"0002001011-25-000029","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000029/edgardoc.xml","form_type":"4"}},{"id":1220649,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-06T23:54:55.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":93476,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter."}],"balance_after":93476,"derivative":{"exercise_price":115.26,"expiration_date":"2035-03-04","underlying":"Common Stock","underlying_shares":93476},"source":{"system":"sec-edgar","filing":"0002001011-25-000014","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000014/edgardoc.xml","form_type":"4"}},{"id":1220648,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-06T23:54:55.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":21382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":151724,"source":{"system":"sec-edgar","filing":"0002001011-25-000014","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000014/edgardoc.xml","form_type":"4"}},{"id":1262011,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-20T01:44:48.000Z","date":"2025-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":4255,"price":120,"value":510600.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":130342,"source":{"system":"sec-edgar","filing":"0002001011-25-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000013/edgardoc.xml","form_type":"4"}},{"id":1262010,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-20T01:44:48.000Z","date":"2025-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":2231,"price":120,"value":267720.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":134597,"source":{"system":"sec-edgar","filing":"0002001011-25-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000013/edgardoc.xml","form_type":"4"}},{"id":1262009,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-20T01:44:48.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":6966,"price":120,"value":835920.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units."}],"balance_after":136828,"source":{"system":"sec-edgar","filing":"0002001011-25-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000013/edgardoc.xml","form_type":"4"}},{"id":1262008,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-20T01:44:48.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":20784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs)."}],"balance_after":143794,"source":{"system":"sec-edgar","filing":"0002001011-25-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000013/edgardoc.xml","form_type":"4"}},{"id":1328229,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-18T01:44:40.000Z","date":"2024-12-13","kind":"grant","planned":false,"acquired":true,"shares":24700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest and become exercisable in 36 equal monthly installments through the third anniversary of the grant date."}],"balance_after":24700,"derivative":{"exercise_price":13.6,"expiration_date":"2034-12-13","underlying":"Common Stock","underlying_shares":24700},"source":{"system":"sec-edgar","filing":"0001062993-24-020821","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000106299324020821/form4.xml","form_type":"4"}},{"id":1363375,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-11-15T21:22:20.000Z","date":"2024-11-13","kind":"grant","planned":false,"acquired":true,"shares":49605,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 49,605 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 49,605 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters."}],"balance_after":263306,"derivative":{"exercise_price":0.64,"expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":49605},"source":{"system":"sec-edgar","filing":"0001753926-24-001951","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392624001951/ownership.xml","form_type":"4"}},{"id":1437426,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-09T21:52:17.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":97.3922,"value":243480.5,"ownership":{"direct":true},"balance_after":123010,"source":{"system":"sec-edgar","filing":"0002001011-24-000067","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000067/edgardoc.xml","form_type":"4"}},{"id":1464306,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-02T23:44:36.000Z","date":"2024-06-28","kind":"other","planned":false,"acquired":true,"shares":350,"price":60.707,"value":21247.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":120510,"source":{"system":"sec-edgar","filing":"0002001011-24-000062","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000062/edgardoc.xml","form_type":"4"}},{"id":1474767,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-19T00:00:40.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":128977,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 128,977 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 128,977 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years."}],"balance_after":213701,"derivative":{"exercise_price":1.3,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":128977},"source":{"system":"sec-edgar","filing":"0001753926-24-001127","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392624001127/ownership.xml","form_type":"4"}},{"id":1559948,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-03-27T21:47:59.000Z","date":"2024-03-25","kind":"exercise","planned":false,"acquired":false,"shares":2156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This Option was previously reported as a Grant of 2,468 shares, which vested in full on June 4, 2021, at an exercise price of $117.58 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":0,"derivative":{"exercise_price":68.51,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":2156},"source":{"system":"sec-edgar","filing":"0002001011-24-000035","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000035/edgardoc.xml","form_type":"4"}},{"id":1559947,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-03-27T21:47:59.000Z","date":"2024-03-25","kind":"exercise","planned":false,"acquired":false,"shares":2855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Option was previously reported as a Grant of 3,269 shares, which vested in full on June 4, 2022, at an exercise price of $115.39 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":0,"derivative":{"exercise_price":67.24,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":2855},"source":{"system":"sec-edgar","filing":"0002001011-24-000035","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000035/edgardoc.xml","form_type":"4"}},{"id":1559946,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-03-27T21:47:59.000Z","date":"2024-03-25","kind":"exercise","planned":false,"acquired":false,"shares":3556,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 9, 2020, at an exercise price of $113.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":0,"derivative":{"exercise_price":66.19,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":3556},"source":{"system":"sec-edgar","filing":"0002001011-24-000035","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000035/edgardoc.xml","form_type":"4"}},{"id":1559945,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-03-27T21:47:59.000Z","date":"2024-03-25","kind":"exercise","planned":false,"acquired":false,"shares":7448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Option was previously reported as a Grant of 4,340 shares at an exercise price of $79.29 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on June 10, 2023."}],"balance_after":0,"derivative":{"exercise_price":46.2,"expiration_date":"2032-06-10","underlying":"Common Stock","underlying_shares":7448},"source":{"system":"sec-edgar","filing":"0002001011-24-000035","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000035/edgardoc.xml","form_type":"4"}},{"id":1559944,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-27T21:47:59.000Z","date":"2024-03-25","kind":"exercise","planned":false,"acquired":true,"shares":3556,"price":66.19,"value":235371.64,"ownership":{"direct":true},"balance_after":120160,"source":{"system":"sec-edgar","filing":"0002001011-24-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000035/edgardoc.xml","form_type":"4"}},{"id":1559943,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-27T21:47:59.000Z","date":"2024-03-25","kind":"exercise","planned":false,"acquired":true,"shares":2156,"price":68.51,"value":147707.56,"ownership":{"direct":true},"balance_after":116604,"source":{"system":"sec-edgar","filing":"0002001011-24-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000035/edgardoc.xml","form_type":"4"}},{"id":1559942,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-27T21:47:59.000Z","date":"2024-03-25","kind":"exercise","planned":false,"acquired":true,"shares":2855,"price":67.24,"value":191970.2,"ownership":{"direct":true},"balance_after":114448,"source":{"system":"sec-edgar","filing":"0002001011-24-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000035/edgardoc.xml","form_type":"4"}},{"id":1559941,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-27T21:47:59.000Z","date":"2024-03-25","kind":"exercise","planned":false,"acquired":true,"shares":7448,"price":46.2,"value":344097.6,"ownership":{"direct":true},"balance_after":111593,"source":{"system":"sec-edgar","filing":"0002001011-24-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000035/edgardoc.xml","form_type":"4"}},{"id":1611029,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-29T23:49:56.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":131723,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter."}],"balance_after":131723,"derivative":{"exercise_price":89.2,"expiration_date":"2034-02-27","underlying":"Common Stock","underlying_shares":131723},"source":{"system":"sec-edgar","filing":"0002001011-24-000027","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000027/edgardoc.xml","form_type":"4"}},{"id":1611028,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-02-29T23:49:56.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":32436,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":104145,"source":{"system":"sec-edgar","filing":"0002001011-24-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000027/edgardoc.xml","form_type":"4"}},{"id":1622062,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Secured Convertible Promissory Note","published_at":"2024-02-23T22:15:39.000Z","date":"2024-02-21","kind":"exercise","planned":false,"acquired":false,"reported_value":175000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the face amount of $175,000 this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 29,167 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, which is $6.00 per share."}],"balance_after":0,"derivative":{"exercise_price":4.8,"exercise_date":"2024-02-21","expiration_date":"2024-02-29","underlying":"Common Stock","underlying_shares":29167},"source":{"system":"sec-edgar","filing":"0001753926-24-000374","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392624000374/ownership.xml","form_type":"4"}},{"id":1622061,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-23T22:15:39.000Z","date":"2024-02-21","kind":"exercise","planned":false,"acquired":true,"shares":29167,"price":4.8,"value":140001.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the face amount of $175,000 this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 29,167 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, which is $6.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the face amount of $175,000 this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 29,167 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, which is $6.00 per share."}],"balance_after":29167,"source":{"system":"sec-edgar","filing":"0001753926-24-000374","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392624000374/ownership.xml","form_type":"4"}},{"id":1639463,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-02-17T01:10:16.000Z","date":"2024-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1381,"price":74.65,"value":103091.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":71709,"source":{"system":"sec-edgar","filing":"0002001011-24-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000016/edgardoc.xml","form_type":"4"}},{"id":1774201,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-09-25T20:44:43.000Z","date":"2023-09-22","kind":"purchase","planned":false,"acquired":true,"shares":4000,"price":59.3822,"value":237528.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $58.975 to $59.930. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":73090,"source":{"system":"sec-edgar","filing":"0000886163-23-000057","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000057/edgardoc.xml","form_type":"4"}},{"id":1857828,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-06-13T22:52:57.000Z","date":"2023-06-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":420,"price":73.76,"value":30979.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number reflected in Column 5 reconciles the total number of shares beneficially held following the transactions reported herein."}],"balance_after":69090,"source":{"system":"sec-edgar","filing":"0000886163-23-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000038/edgardoc.xml","form_type":"4"}},{"id":1991375,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-28T01:50:53.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":46178,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from February 23, 2023, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after February 23, 2023 and the remaining stock options vesting in 42 equal monthly installments thereafter."}],"balance_after":46178,"derivative":{"exercise_price":75.09,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":46178},"source":{"system":"sec-edgar","filing":"0000899243-23-006294","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000089924323006294/doc4.xml","form_type":"4"}},{"id":1991374,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-28T01:50:53.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":17005,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three equal annual installments on February 15, 2024; February 15, 2025; and February 15, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":68791,"source":{"system":"sec-edgar","filing":"0000899243-23-006294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000089924323006294/doc4.xml","form_type":"4"}},{"id":2076330,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-12-27T23:26:42.000Z","date":"2022-12-22","kind":"grant","acquired":true,"shares":2081,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from the date of grant, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after the date of grant and the remaining stock options vesting in 42 equal monthly installments thereafter."}],"balance_after":2081,"derivative":{"exercise_price":67.03,"expiration_date":"2032-12-22","underlying":"Common Stock","underlying_shares":2081},"source":{"system":"sec-edgar","filing":"0000899243-22-039399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000089924322039399/doc4.xml","form_type":"4"}},{"id":2094982,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-12-07T01:25:57.000Z","date":"2022-12-05","kind":"grant","acquired":true,"shares":132000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from the date of grant, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after the date of grant and the remaining stock options vesting in 42 equal monthly installments thereafter."}],"balance_after":132000,"derivative":{"exercise_price":69.7,"expiration_date":"2032-12-05","underlying":"Common Stock","underlying_shares":132000},"source":{"system":"sec-edgar","filing":"0000899243-22-037822","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000089924322037822/doc4.xml","form_type":"4"}},{"id":2192769,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-08-08T22:26:07.000Z","date":"2022-08-04","kind":"grant","acquired":true,"shares":44224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant."}],"balance_after":44224,"derivative":{"exercise_price":3.91,"expiration_date":"2032-08-03","underlying":"Common Stock","underlying_shares":44224},"source":{"system":"sec-edgar","filing":"0001437749-22-019437","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774922019437/rdgdoc.xml","form_type":"4"}},{"id":2192768,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-08-08T22:26:07.000Z","date":"2022-08-04","kind":"grant","acquired":true,"shares":7375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant."}],"balance_after":125905,"source":{"system":"sec-edgar","filing":"0001437749-22-019437","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774922019437/rdgdoc.xml","form_type":"4"}},{"id":2234864,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-13T22:46:41.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":4340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":4340,"derivative":{"exercise_price":79.29,"expiration_date":"2032-06-10","underlying":"Common Stock","underlying_shares":4340},"source":{"system":"sec-edgar","filing":"0000886163-22-000082","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000082/edgardoc.xml","form_type":"4"}},{"id":2234863,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-13T22:46:41.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":1004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":51786,"source":{"system":"sec-edgar","filing":"0000886163-22-000082","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000082/edgardoc.xml","form_type":"4"}},{"id":2321928,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-03-22T17:12:01.000Z","date":"2022-03-22","kind":"disposition_to_issuer","acquired":false,"shares":85760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":3.66,"underlying":"Common Stock","underlying_shares":85760},"source":{"system":"sec-edgar","filing":"0001103021-22-000066","document":"wf-form4_164798349975965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000066/wf-form4_164798349975965.xml","form_type":"4"}},{"id":2321927,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-03-22T17:12:01.000Z","date":"2022-03-22","kind":"disposition_to_issuer","acquired":false,"shares":48123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"exercise_price":2.93,"underlying":"Common Stock","underlying_shares":48123},"source":{"system":"sec-edgar","filing":"0001103021-22-000066","document":"wf-form4_164798349975965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000066/wf-form4_164798349975965.xml","form_type":"4"}},{"id":2321926,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-03-22T17:12:01.000Z","date":"2022-03-22","kind":"disposition_to_issuer","acquired":false,"shares":22685,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":22685},"source":{"system":"sec-edgar","filing":"0001103021-22-000066","document":"wf-form4_164798349975965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000066/wf-form4_164798349975965.xml","form_type":"4"}},{"id":2321925,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-22T17:12:01.000Z","date":"2022-03-22","kind":"other","acquired":false,"shares":252207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., (\"Parent\"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of March 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., (\"Parent\"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of March 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., (\"Parent\"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of March 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001103021-22-000066","document":"wf-form4_164798349975965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000066/wf-form4_164798349975965.xml","form_type":"4"}},{"id":2419637,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-02-01T16:06:02.000Z","date":"2022-01-27","kind":"exercise","acquired":false,"shares":7684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (\"the Plan\"). The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."}],"balance_after":7685,"derivative":{"exercise_price":0,"expiration_date":"2023-01-27","underlying":"Common Stock","underlying_shares":7684},"source":{"system":"sec-edgar","filing":"0001103021-22-000027","document":"wf-form4_164374953768049.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000027/wf-form4_164374953768049.xml","form_type":"4"}},{"id":2419636,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-02-01T16:06:02.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":15369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (\"the Plan\"). The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (\"the Plan\"). The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."}],"balance_after":15369,"derivative":{"exercise_price":0,"expiration_date":"2023-01-27","underlying":"Common Stock","underlying_shares":15369},"source":{"system":"sec-edgar","filing":"0001103021-22-000027","document":"wf-form4_164374953768049.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000027/wf-form4_164374953768049.xml","form_type":"4"}},{"id":2419635,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-02-01T16:06:02.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":85760,"price":3.66,"value":313881.6,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The stock options were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Plan. The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Plan. The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."}],"balance_after":85760,"derivative":{"exercise_price":3.66,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":85760},"source":{"system":"sec-edgar","filing":"0001103021-22-000027","document":"wf-form4_164374953768049.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000027/wf-form4_164374953768049.xml","form_type":"4"}},{"id":2419634,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-01T16:06:02.000Z","date":"2022-01-27","kind":"exercise","acquired":true,"shares":7684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were issued to the Reporting Person on January 27, 2022, as compensation for service on the Issuer's board of directors, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (\"the Plan\"). The award is subject to time-based vesting and vests in equal portions on: (i) January 27, 2022; and (ii) January 27, 2023."}],"balance_after":252207,"source":{"system":"sec-edgar","filing":"0001103021-22-000027","document":"wf-form4_164374953768049.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302122000027/wf-form4_164374953768049.xml","form_type":"4"}},{"id":2460406,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-12-23T23:07:59.000Z","date":"2021-12-22","kind":"gift","acquired":false,"shares":1470,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents a gift / charitable donation effective December 22, 2021. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares."}],"balance_after":118530,"source":{"system":"sec-edgar","filing":"0001437749-21-029223","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774921029223/rdgdoc.xml","form_type":"4"}},{"id":2608814,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-08-10T18:15:30.000Z","date":"2021-08-06","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest as follows: (i) 15,000 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":15000,"derivative":{"exercise_price":0,"expiration_date":"2022-08-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001103021-21-000068","document":"wf-form4_162863369796370.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302121000068/wf-form4_162863369796370.xml","form_type":"4"}},{"id":2608813,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-10T18:15:30.000Z","date":"2021-08-06","kind":"exercise","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":244523,"source":{"system":"sec-edgar","filing":"0001103021-21-000068","document":"wf-form4_162863369796370.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302121000068/wf-form4_162863369796370.xml","form_type":"4"}},{"id":2665302,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T23:25:48.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":15097,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest on the earlier of the date of the 2022 annual meeting of stockholders of the Issuer and June 16, 2022, the first anniversary of the date of the grant."}],"balance_after":15097,"derivative":{"exercise_price":7.79,"expiration_date":"2031-06-15","underlying":"Common stock","underlying_shares":15097},"source":{"system":"sec-edgar","filing":"0001437749-21-015110","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774921015110/rdgdoc.xml","form_type":"4"}},{"id":2671164,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T20:13:34.000Z","date":"2019-11-18","kind":"grant","acquired":true,"shares":54720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest annually over three years from the vesting commencement date of October 25, 2019, the date of the grantee's appointment as a director of Vaxart, Inc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This amendment is being filed solely to correct the expiration date of the stock option which was erroneously reported as October 24, 2029, in the original filing on November 20, 2019."}],"balance_after":54720,"derivative":{"exercise_price":0.31,"expiration_date":"2029-11-17","underlying":"Common Stock","underlying_shares":54720},"source":{"system":"sec-edgar","filing":"0001437749-21-014721","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774921014721/rdgdoc.xml","form_type":"4/A","original_submission_date":"2019-11-20"}},{"id":2680010,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-06-08T01:25:22.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":3269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":3269,"derivative":{"exercise_price":115.39,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":3269},"source":{"system":"sec-edgar","filing":"0000886163-21-000092","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616321000092/edgardoc.xml","form_type":"4"}},{"id":2680009,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-08T01:25:22.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":50782,"source":{"system":"sec-edgar","filing":"0000886163-21-000092","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616321000092/edgardoc.xml","form_type":"4"}},{"id":2859891,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-16T16:02:48.000Z","date":"2018-12-26","kind":"gift","acquired":false,"shares":3391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 26, 2018, the Reporting Person donated 3,391 shares of the Company's common stock to a foundation.  The Reporting Person disclaims beneficial ownership of common stock held by this foundation."}],"balance_after":214523,"source":{"system":"sec-edgar","filing":"0001103021-21-000022","document":"wf-form5_161350934150439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302121000022/wf-form5_161350934150439.xml","form_type":"5"}},{"id":2864574,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-02-12T23:23:48.000Z","date":"2021-02-11","kind":"exercise","acquired":false,"shares":2474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":195.91,"expiration_date":"2028-06-18","underlying":"Common Stock","underlying_shares":2474},"source":{"system":"sec-edgar","filing":"0000886163-21-000035","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616321000035/edgardoc.xml","form_type":"4"}},{"id":2864573,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T23:23:48.000Z","date":"2021-02-11","kind":"exercise","acquired":true,"shares":2474,"price":195.91,"value":484681.34,"ownership":{"direct":true},"balance_after":50152,"source":{"system":"sec-edgar","filing":"0000886163-21-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616321000035/edgardoc.xml","form_type":"4"}},{"id":2864572,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T23:23:48.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":5083,"price":213.1438,"value":1083409.9354,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.84 to $214.58, inclusive.  The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":47678,"source":{"system":"sec-edgar","filing":"0000886163-21-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616321000035/edgardoc.xml","form_type":"4"}},{"id":2894005,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-01-28T00:02:09.000Z","date":"2021-01-27","kind":"exercise","acquired":false,"shares":2456,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":113.5,"expiration_date":"2027-05-25","underlying":"Common Stock","underlying_shares":2456},"source":{"system":"sec-edgar","filing":"0000886163-21-000012","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616321000012/edgardoc.xml","form_type":"4"}},{"id":2894004,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-28T00:02:09.000Z","date":"2021-01-27","kind":"exercise","acquired":true,"shares":2456,"price":113.5,"value":278756.0,"ownership":{"direct":true},"balance_after":52761,"source":{"system":"sec-edgar","filing":"0000886163-21-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616321000012/edgardoc.xml","form_type":"4"}},{"id":3051345,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-20T16:16:45.000Z","date":"2020-08-18","kind":"sale","acquired":false,"shares":50000,"price":4.99,"value":249500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 18, 2020, the Reporting Person sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $4.99 per share. The highest sale price for the Common Stock was $5.03 per share and the lowest sale price was $4.98 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes."}],"balance_after":217914,"source":{"system":"sec-edgar","filing":"0001103021-20-000140","document":"wf-form4_159795459193844.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302120000140/wf-form4_159795459193844.xml","form_type":"4"}},{"id":3062258,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-08-11T16:50:37.000Z","date":"2020-08-07","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest as follows: (i) 30,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iI) 15,000 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":45000,"derivative":{"exercise_price":0,"expiration_date":"2022-08-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001103021-20-000121","document":"wf-form4_159717902434587.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302120000121/wf-form4_159717902434587.xml","form_type":"4"}},{"id":3062257,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-11T16:50:37.000Z","date":"2020-08-07","kind":"exercise","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest as follows: (i) 30,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iI) 15,000 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":267914,"source":{"system":"sec-edgar","filing":"0001103021-20-000121","document":"wf-form4_159717902434587.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302120000121/wf-form4_159717902434587.xml","form_type":"4"}},{"id":3112443,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-06-12T22:34:48.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":2468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2468,"derivative":{"exercise_price":117.58,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":2468},"source":{"system":"sec-edgar","filing":"0000886163-20-000078","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616320000078/edgardoc.xml","form_type":"4"}},{"id":3112442,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T22:34:48.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":50305,"source":{"system":"sec-edgar","filing":"0000886163-20-000078","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616320000078/edgardoc.xml","form_type":"4"}},{"id":3117942,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2020-06-09T20:42:09.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":65700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest on the first anniversary of the 2020 annual meeting of stockholders of the Issuer."}],"balance_after":65700,"derivative":{"exercise_price":2.39,"exercise_date":"2021-06-08","expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":65700},"source":{"system":"sec-edgar","filing":"0001437749-20-012746","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774920012746/rdgdoc.xml","form_type":"4"}},{"id":3167047,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true}}],"security":"Common stock","published_at":"2020-04-30T20:10:53.000Z","date":"2020-04-28","kind":"sale","acquired":false,"shares":60000,"price":3.275,"value":196500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $3.26 to $3.29, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":120000,"source":{"system":"sec-edgar","filing":"0001437749-20-009007","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774920009007/rdgdoc.xml","form_type":"4"}},{"id":3365297,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2019-11-20T23:55:54.000Z","date":"2019-11-18","kind":"grant","acquired":true,"shares":54720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest annually over three years from the vesting commencement date of October 25, 2019, the date of the grantee's appointment as a director of Vaxart, Inc."}],"balance_after":54720,"derivative":{"exercise_price":0.31,"expiration_date":"2029-10-24","underlying":"Common Stock","underlying_shares":54720},"source":{"system":"sec-edgar","filing":"0001437749-19-023307","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774919023307/rdgdoc.xml","form_type":"4"}},{"id":3366415,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-19T16:38:11.000Z","date":"2019-11-15","kind":"sale","acquired":false,"shares":200000,"price":6.11,"value":1222000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 15, 2019, the Reporting Person sold an aggregate of 200,000 shares of the Issuer's Common Stock at a weighted average price of $6.11 per share. The highest sale price for the Common Stock was $6.30 per share and the lowest sale price was $6.01 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes."}],"balance_after":237914,"source":{"system":"sec-edgar","filing":"0001103021-19-000038","document":"wf-form4_157419947661243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302119000038/wf-form4_157419947661243.xml","form_type":"4"}},{"id":3437808,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-08-15T16:27:03.000Z","date":"2019-08-13","kind":"exercise","acquired":false,"shares":18123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest as follows: (i) 30,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (ii) 30,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iii) 15,000 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":75000,"derivative":{"exercise_price":0,"expiration_date":"2022-08-01","underlying":"Common Stock","underlying_shares":18123},"source":{"system":"sec-edgar","filing":"0001103021-19-000007","document":"wf-form4_156590080736819.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302119000007/wf-form4_156590080736819.xml","form_type":"4"}},{"id":3437807,"issuer":{"id":128876,"kind":"organization","name":"BIODELIVERY SCIENCES INTERNATIONAL INC","symbol":"BDSI"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-15T16:27:03.000Z","date":"2019-08-13","kind":"exercise","acquired":true,"shares":18123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs vest as follows: (i) 30,000 RSUs vest in the first open window following the Company's 2020 Annual Meeting of Stockholders, (ii) 30,000 RSUs vest in the first open window following the Company's 2021 Annual Meeting of Stockholders and (iii) 15,000 RSUs vest in the first open window following the Company's 2022 Annual Meeting of Stockholders."}],"balance_after":437914,"source":{"system":"sec-edgar","filing":"0001103021-19-000007","document":"wf-form4_156590080736819.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1103021/000110302119000007/wf-form4_156590080736819.xml","form_type":"4"}},{"id":3447919,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-05T23:04:06.000Z","date":"2019-08-02","kind":"purchase","acquired":true,"shares":1000,"price":93.5944,"value":93594.4,"ownership":{"direct":true},"balance_after":49474,"source":{"system":"sec-edgar","filing":"0000886163-19-000140","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000140/edgardoc.xml","form_type":"4"}},{"id":3497944,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-06-07T22:54:10.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":4071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":4071,"derivative":{"exercise_price":113.59,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":4071},"source":{"system":"sec-edgar","filing":"0000886163-19-000107","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000107/edgardoc.xml","form_type":"4"}},{"id":3497943,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-07T22:54:10.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":48474,"source":{"system":"sec-edgar","filing":"0000886163-19-000107","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616319000107/edgardoc.xml","form_type":"4"}},{"id":3791492,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-10-15T16:55:04.000Z","date":"2018-10-12","kind":"exercise","acquired":false,"shares":2329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 23, 2016.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":119.3,"expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":2329},"source":{"system":"sec-edgar","filing":"0000886163-18-000152","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616318000152/edgardoc.xml","form_type":"4"}},{"id":3791491,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-10-15T16:55:04.000Z","date":"2018-10-12","kind":"exercise","acquired":false,"shares":2754,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on April 24, 2015.  Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":89.75,"expiration_date":"2025-04-24","underlying":"Common Stock","underlying_shares":2754},"source":{"system":"sec-edgar","filing":"0000886163-18-000152","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616318000152/edgardoc.xml","form_type":"4"}},{"id":3791490,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-15T16:55:04.000Z","date":"2018-10-12","kind":"exercise","acquired":true,"shares":2329,"price":119.3,"value":277849.7,"ownership":{"direct":true},"balance_after":47639,"source":{"system":"sec-edgar","filing":"0000886163-18-000152","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616318000152/edgardoc.xml","form_type":"4"}},{"id":3791489,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-15T16:55:04.000Z","date":"2018-10-12","kind":"exercise","acquired":true,"shares":2754,"price":89.75,"value":247171.5,"ownership":{"direct":true},"balance_after":45310,"source":{"system":"sec-edgar","filing":"0000886163-18-000152","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000088616318000152/edgardoc.xml","form_type":"4"}}],"next_cursor":"2018-10-15T16:55:04.000000Z,3791489"}